Randomized trial of posaconazole and benznidazole for chronic Chagas' disease

New England Journal of Medicine

Volumn 370, Issue 20, 2014, Pages 1899-1908

  Molina, Israel ^a,e   Goḿez I Prat, Jordi ^a,e   Salvador, Fernando ^a,e   Treviño, Begoña ^a,e   Sulleiro, Elena ^b,e   Serre, Núria ^a,e   Pou, Diana ^a,e   Roure, Sílvia ^f   Cabezos, Juan ^a,e   Valerio, Lluís ^g   Blanco Grau, Albert ^c   Sánchez Montalv́a, Adrián ^a,e   Vidal, Xavier ^d,h   Pahissa, Albert ^a,e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Microbiology Unit   (Spain)

^c ICS   (Spain)

^d Pharmacology Department   (Spain)

^e INSTITUT CATALÀ DE LA SALUT   (Spain)

^f Germans Trias i Pujol University Hospital   (Spain)

^g International Health Unit Metropolitana Nord   (Spain)

^h UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BENZNIDAZOLE; GAMMA GLUTAMYLTRANSFERASE; POSACONAZOLE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTHENIA; CHAGAS DISEASE; CHRONIC DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIZZINESS; DNA DETERMINATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSAL DRYNESS; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; PARASITE CONTROL; PARASITE EXAMINATION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN MANIFESTATION; SOMNOLENCE; TREATMENT DURATION; TREATMENT FAILURE; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT;

ADULT; CHAGAS DISEASE; CHRONIC DISEASE; DNA, PROTOZOAN; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; NITROIMIDAZOLES; PROSPECTIVE STUDIES; TRANSAMINASES; TREATMENT OUTCOME; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84900311830     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1313122     Document Type: Article

References (35)

1. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010;375:1388-402.
2. Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011;364:2527-34.
3. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998;59:526-9. (Pubitemid 28480704)
4. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348:1407-13. (Pubitemid 26395235)
5. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144:724-34. (Pubitemid 46780632)
6. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007;40:1-10. (Pubitemid 46759236)
7. Hasslocher-Moreno AM, do Brasil PEAA, de Sousa AS, Xavier SS, Chambela MC, Sperandio da Silva GM. Safety of benznidazole use in the treatment of chronic Chagas' disease. J Antimicrob Chemother 2012;67:1261-6.
8. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010;115:55-68.
9. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 2007;8:1167-78. (Pubitemid 46937838)
10. Urbina JA, Payares G, Contreras LM, et al. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 1998;42:1771-7. (Pubitemid 28311577)
11. Molina J, Martins-Filho O, Brener Z, Romanha AJ, Loebenberg D, Urbina JA. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000;44:150-5. (Pubitemid 30010686)
12. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arq Bras Cardiol 1985;45:249-56. (In Spanish.)
13. de Rezende J, Lauar KM, de Oliveira A. Clinical and radiological aspects of aperistalsis of the esophagus. Rev Bras Gastroenterol 1960;12:247-62. (In Portuguese.)
14. Ximenes CA. Tecnica simplificada para o diagnóstico radiológico do megacolo chagásico. Rev Soc Bras Med Trop 1984;17:23.
15. Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852:223-8. (Pubitemid 46839210)
16. Piron M, Fisa R, Casamitjana N, et al. Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop 2007;103:195-200. (Pubitemid 47307326)
17. Sun J. A non-parametric test for interval-censored failure time data with application to AIDS studies. Stat Med 1996;15:1387-95. (Pubitemid 26242548)
18. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2012.
19. Coura JR, de Abreu LL, Willcox HP, Petana W. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation. Rev Soc Bras Med Trop 1997;30:139-44. (In Portuguese.) (Pubitemid 27179523)
20. Lauria-Pires L, Braga MS, Vexenat AC, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000;63:111-8. (Pubitemid 32488345)
21. Gallerano RR, Sosa RR. Interventional study in the natural evolution of Chagas disease: evaluation of specific antiparasitic treatment: retrospective-prospective study of antiparasitic therapy. Rev Fac Cien Med Univ Nac Cordoba 2000;57:135-62. (In Spanish.)
22. Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA. Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina. Rev Soc Bras Med Trop 2004;37:365-75. (In Portuguese.) (Pubitemid 39287095)
23. de Castro AM, Luquetti AO, Rassi A, Chiari E, Galvão LM. Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection. Parasitol Res 2006;99:379-83. (Pubitemid 44426728)
24. Braga MS, Lauria-Pires L, Argañaraz ER, Nascimento RJ, Teixeira AR. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop Sao Paulo 2000;42:157-61. (Pubitemid 32229947)
25. Fernandes CD, Tiecher FM, Balbinot MM, et al. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 2009;104:27-32.
26. Lana M, Lopes LA, Martins HR, et al. Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment. Mem Inst Oswaldo Cruz 2009;104:1139-47.
27. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009;64:1139-47.
28. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007;298:2171-81. (Pubitemid 350106656)
29. Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz 2011;106:641-5.
30. Matta Guedes PM, Gutierrez FRS, Nascimento MSL, Do-Valle-Matta MA, Silva JS. Antiparasitical chemotherapy in Chagas' disease: current evidence. Trop Med Int Health 2012;17:1057-65.
31. Pinazo M-J, Espinosa G, Gállego M, López-Chejade PL, Urbina JA, Gascón J. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010;82:583-7.
32. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66. (Pubitemid 43190980)
33. Maldonado RA, Molina J, Payares G, Urbina JA. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrob Agents Chemother 1993;37:1353-9. (Pubitemid 23166739)
34. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66.
35. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 2002;44:29-37. (Pubitemid 34205107)